整合素αV在胸主动脉瘤与夹层中作为潜在治疗靶点及其警示意义
研究通过TMT定量蛋白质组学分析A型主动脉夹层患者血浆,发现整合素αV和αL显著下调;在小鼠TAA模型中,药物抑制整合素αV(西仑吉肽或SB273005)加重升主动脉TAA发展并破坏弹性纤维,加剧促炎反应并干扰SMC收缩表型转化,STAT1负调控整合素αV介导的SMC表型调节。结论提示整合素αV是TAA干预的有前景靶点,但需警惕其抑制剂在临床试验中可能增加TAA/AD风险。
要点
- 整合素αV在主动脉中膜平滑肌细胞高表达,夹层后表达显著降低
- 药物抑制整合素αV加重小鼠升主动脉TAA及弹性纤维紊乱丢失
- 整合素αV抑制剂在癌症试验中需警惕增加TAA/AD风险
核心结论
- 整合素αV是TAA干预的有前景分子靶点,但临床使用其抑制剂需警惕可能增加TAA或AD风险。
研究设计与样本
- 基于TMT的A型主动脉夹层患者血浆定量蛋白质组学分析。
- 采用β-氨基丙腈诱导的小鼠TAA模型,结合RNA测序转录组学及免疫组化、免疫荧光、Western blot、免疫共沉淀和生物信息学分析。
主要发现
- A型主动脉夹层患者血浆中整合素αV和整合素αL显著下调。
- 整合素αV在主动脉中膜尤其平滑肌细胞中丰富表达,夹层后表达显著降低。
- 西仑吉肽或SB273005药物抑制整合素αV显著加重升主动脉TAA发展,伴弹性纤维严重紊乱和丢失。
- Bulk RNA测序显示抑制整合素αV加剧TAA进展中的促炎反应。
- 抑制整合素αV破坏SMC向收缩表型转化,STAT1负调控整合素αV介导的SMC表型调节。
临床怎么用
- 整合素αV抑制剂在癌症临床试验中应用时,需监测胸主动脉瘤或夹层风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Thoracic aortic aneurysm (TAA) is a life-threatening condition that predisposes to aortic dissection (AD), yet its underlying pathophysiologic mechanisms remain poorly understood. METHODS: Tandem mass tag-based quantitative proteomics of plasma from type A AD patients was performed to identify dysregulated proteins. The β-aminopropionitrile-induced mouse model was used to experimentally recapitulate TAA progression, with disease mechanisms further characterized through RNA sequencing transcriptomics, complemented by comprehensive molecular analyses including immunohistochemistry, immunofluorescence, western blot, co-immunoprecipitation, and bioinformatics integration. RESULTS: Integrin αV and integrin αL were significantly downregulated proteins in plasma samples from patients with type A AD. Integrin αV abundantly expressed in the aortic media, particularly in smooth muscle cells (SMCs), with significantly reduced expression after dissection. Pharmacologic inhibition of integrin αV with cilengitide or SB273005 markedly aggravated ascending TAA development, accompanied by severe disorganization and loss of elastic fibers. Bulk RNA sequencing revealed that integrin αV inhibition exacerbated proinflammatory responses during TAA progression. Inhibiting integrin αV disrupted the SMC transition to a contractile phenotype, whereas STAT1 negatively regulated integrin αV-mediated SMC phenotypic modulation. CONCLUSIONS: These findings identify integrin αV as a promising molecular target for TAA intervention. However, they also highlight concerns regarding the clinical use of integrin αV inhibitors, which are currently under investigation in cancer trials because they may increase the risk of TAA or AD development.
引用
- Su SA, Zhu Y, Feng Z, et al. Integrin αV emerges as a potential therapeutic target with cautionary implications in thoracic aortic aneurysm and dissection. J Thorac Cardiovasc Surg. 2025. PMID: 41077125. doi:10.1016/j.jtcvs.2025.10.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。